The use of cannabis for people with Alzheimer’s disease is a topic of increasing interest, as some studies suggest it may offer symptom relief and potentially reduce inflammation associated with the disease. However, it is crucial to approach this topic with caution, considering both the potential benefits and risks.
Alzheimer’s disease is a progressive neurological disorder that causes the brain to shrink and brain cells to die. It is the most common cause of dementia, leading to a decline in cognitive function, memory loss, and eventually physical decline. Current treatments focus on managing symptoms rather than reversing the disease progression.
Cannabis, particularly its non-psychoactive compound cannabidiol (CBD), has been studied for its potential to reduce inflammation in the brain, which is believed to play a significant role in Alzheimer’s disease progression. A study published in the journal eNeuro found that inhaled CBD reduced inflammatory markers in the brain and improved memory-related behaviors in mice with Alzheimer’s-like conditions [2][3]. This suggests that CBD could be a promising therapeutic agent targeting the immune system’s role in Alzheimer’s.
However, while cannabis may offer some benefits in symptom management, such as reducing agitation and improving sleep, it does not slow or reverse Alzheimer’s disease progression [1]. THC, the psychoactive component of cannabis, has been shown to reduce agitation and appetite loss in Alzheimer’s patients, but its effects on cognition are mixed [7].
For older adults, including those with Alzheimer’s, there are significant risks associated with cannabis use. Regular cannabis use has been linked to increased risks of heart attacks and strokes, particularly when combined with tobacco or alcohol [5]. Additionally, cannabis can cause confusion and dizziness, increasing the risk of falls, which is a significant concern for older adults [5].
Moreover, there is evidence suggesting that disordered marijuana use may be linked to an increased risk of dementia, although this is not directly related to therapeutic use in Alzheimer’s patients [8]. The impact of cannabis on cognition is also a concern, as it can impair memory and learning, especially in older adults [1].
Given these considerations, while cannabis may offer some symptom relief for Alzheimer’s patients, it should be used under medical supervision. There is not enough clinical evidence to support cannabis as a long-term treatment for dementia, and its use must be carefully weighed against potential risks [6].
In conclusion, the decision to use cannabis for Alzheimer’s disease should be made with caution and under the guidance of healthcare professionals. It is essential to monitor both the benefits and risks closely, especially in older adults.
References:
[1] https://doktorhigh.com/learn-cannabis-alzheimers
[2] https://www.psypost.org/cannabidiol-may-ease-alzheimers-related-brain-inflammation-and-improve-cognition/
[3] https://www.medicalnewstoday.com/articles/cbd-help-treat-reduce-inflammation-alzheimers-disease
[4] https://utahcanna.org/how-cannabis-may-protect-against-age-related-cognitive-decline/
[5] https://med.stanford.edu/news/insights/2025/10/cannabis-marijuana-seniors-cautions.html
[6] https://cannabishealthnews.co.uk/2025/10/16/medical-cannabis-and-dementia-what-does-the-evidence-say/
[7] https://releaf.co.uk/blog/decoding-cannabis-recent-study-on-thc-oil-for-alzheimers-agitation-and-sleep
[8] https://www.nature.com/articles/s44400-025-00037-9
